SCHEMBL2287151

SCHEMBL2287151

Cc1[c]cc(C(C)C)c(O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
TRPA1 O75762 2/20 0.47
SLC6A2 P23975 2/20 0.47
HTR2B P41595 2/20 0.47
CHRM1 P11229 1/20 0.47
ADRA1A P35348 1/20 0.47
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
GABRA1 P14867 6/20 0.38
GABRB2 P47870 4/20 0.38
GABRB1 P18505 4/20 0.35
PKM P14618 2/20 0.34
CYP1A2 P05177 3/20 0.33
PTGS1 P23219 2/20 0.33
CYP3A4 P08684 2/20 0.33
HIF1A Q16665 2/20 0.33
CYP2D6 P10635 2/20 0.33
FAAH O00519 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301891 0.80 LMNA (0.43) LMNATRPA1SLC6A2HTR2BCHRM1
SCHEMBL9802941 0.78 LMNA (0.42) LMNATRPA1SLC6A2HTR2BCHRM1
SCHEMBL10798128 0.74 LMNA (0.39) LMNAGABRA1GABRB1HTT
SCHEMBL929797 0.74
SCHEMBL27585244 0.72 LMNA (0.37) LMNATRPA1SLC6A2HTR2BCHRM1
SCHEMBL930869 0.72
SCHEMBL1819414 0.71 GAA (0.46) LMNAHPGDTSHRMAPTKMT2A
SCHEMBL67859 0.70 LMNA (0.58) LMNATRPA1SLC6A2HTR2BCHRM1
SCHEMBL501283 0.70 LMNA (0.39) LMNATRPA1SLC6A2HTR2BCHRM1
SCHEMBL1492630 0.68 ALDH1A1 (0.34) LMNACYP3A4HPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465882-A4 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2005-04-06 EP claimed
EP-1465882-A2 HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2004-10-13 EP claimed
US-6696473-B2 THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM X-CEPTOR THERAPEUTICS, INC. 2004-02-24 US claimed
WO-2003060078-A9 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2004-02-19 WO claimed
US-20030212111-A1 Heterocyclic modulators of nuclear receptors AKARNA THERAPEUTICS, LTD. (GB) 2003-11-13 US claimed
WO-2003060078-A2 HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-07-24 WO claimed
US-8003297-B2 Polymeric material, containing a latent acid BASF SE (DE) 2011-08-23 US disclosed
US-20100093950-A1 POLYMERIC MATERIAL, CONTAINING A LATENT ACID CIBA CORPORATION 2010-04-15 US disclosed
US-7655380-B2 Polymeric material, containing a latent acid CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-02-02 US disclosed
US-20090155716-A1 Polymeric material containing a latent acid, i.e. a compound which is not an acid but which can be converted to an acid by the influence of laser irradiation HENEGHAN MICHAEL 2009-06-18 US disclosed
EP-1407322-B1 LASER MARKING METHOD CIBA HOLDING INC (CH) 2008-12-17 EP disclosed
US-7264916-B2 Laser marking method CIBA SPECIALTY CHEMICALS CORPORATION (US) 2007-09-04 US disclosed
US-20070054220-A1 Polymeric material, containing a latent acid HENEGHAN MICHAEL 2007-03-08 US disclosed
US-4734519-A STABILIZERS MALLINCKRODT, INC. (US) 1988-03-29 US disclosed
EP-0250087-A1 Pentaerythritol co-esters MALLINCKRODT, INC. (US) 1987-12-23 EP disclosed
US-4539354-A PHOSPHITE DERIVATIVE OF A PHENOL, A GROUP II METAL CARBOXYLATE ANDAN ESTER OF A POLYOL ALLIED CORPORATION (US) 1985-09-03 US disclosed
EP-0032586-B1 DURABLE POLYESTER MOLDING COMPOSITION GAF CORPORATION (US) 1984-01-11 EP disclosed
EP-0069195-A2 Stabilized ethylene/chlorotrifluoroethylene copolymer composition Ausimont, U.S.A., Inc. (US) 1983-01-12 EP disclosed
EP-0032586-A2 Durable polyester molding composition GAF CORPORATION (US) 1981-07-29 EP disclosed
US-4277391-A CONTAINING THREE DIFFERENT TYPES OF ANTIOXIDANTS GAF CORPORATION (US) 1981-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212111-A1 Heterocyclic modulators of nuclear receptors NR1H2, NR1H3, NR1H4 LMNA 2921/4885TRPA1 797/4885SLC6A2 4527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.